Evidence map›Paper›PMID 24189078›Full record

ArticleBMJ open2013

Monitoring the use of lipid-lowering medication among persons with newly diagnosed diabetes: a nationwide register-based study.

Tuulikki Vehko, Reijo Sund, Martti Arffman, Kristiina Manderbacka, Pirjo Ilanne-Parikka, Ilmo Keskimäki

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Multiple Socioeconomic Circumstances and Initiation of Cardiovascular Medication among Ageing Employees.International journal of environmental research and public health · 2021
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Tuulikki VehkoService System Research Unit, National Institute for Health and Welfare (THL), Helsinki, Finland.
Reijo Sund
Martti Arffman
Kristiina Manderbacka
Pirjo Ilanne-Parikka
Ilmo Keskimäki
Finnish Institute for Health and Welfare · FIFinnish Diabetes Association · FITampere University · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo develop a register-based monitoring system to provide information on the use of lipid-lowering medication among persons with diabetes in different patient groups and by socioeconomic position.

designLongitudinal and register-based, before and after diabetes diagnosis.

settingFinnish population.

participantsA total of 121 053 persons aged 30-79 years with a new diagnosis of diabetes during 2000-2006. The annual cohorts were divided at the time of diabetes diagnosis by coronary heart disease (CHD) status. PRIMARY AND SECONDARY OUTCOME MEASURES: Lipid-lowering medication purchases after diabetes diagnosis and prior to the diagnosis.

resultsAccording to the health insurance reimbursement data the use of lipid-lowering medication advanced rapidly among people with diabetes in the early 2000s in Finland. Of the patients diagnosed with diabetes in 2000 only one-fourth used lipid-lowering medication in 6-12 months after their diagnosis. For those diagnosed in 2006, the utilization rate was 46%. Among those with a history of CHD the use of medication was markedly higher; 51-58% in 2000 and 77-79% in 2006. Taking into account the increasing trend and measuring the independent effect of the diagnosis of diabetes on lipid-lowering medication, setting the diagnosis increased the use by 10-50%. Despite increasing overall utilisation rates, socioeconomic difference in the use of lipid-lowering medication remained throughout the study period. In particular, the lowest income quintile differed from other income groups and in 2006 its use of lipid-lowering medication remained approximately 10% points lower compared with the overall level.

conclusionsThe lipid-lowering medication is being applied in an increasing population of new diabetes cases; however, modelling the independent effect of the diagnosis of diabetes on lipid-lowering medication shows that the diagnosis increased use, but did not abolish socioeconomic differences.

Indexed as

DiabetesHealth Service ResearchPharmacology and TherapeuticsResearch Methods

Identifiers

PMID24189078
PMCPMC3822306
OpenAlexW2158379291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.